The Manufacturers Life Insurance Company Takes $250,000 Position in Monopar Therapeutics Inc. $MNPR

The Manufacturers Life Insurance Company purchased a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,572 shares of the company’s stock, valued at approximately $250,000. The Manufacturers Life Insurance Company owned 0.07% of Monopar Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP bought a new position in Monopar Therapeutics during the 3rd quarter worth $18,904,000. Siren L.L.C. bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $13,863,000. Deerfield Management Company L.P. bought a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at about $13,048,000. RA Capital Management L.P. increased its stake in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares during the period. Finally, TCG Crossover Management LLC bought a new position in shares of Monopar Therapeutics during the third quarter worth about $12,496,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $116.49 on Tuesday. Monopar Therapeutics Inc. has a fifty-two week low of $29.18 and a fifty-two week high of $124.82. The stock has a 50 day simple moving average of $97.23 and a two-hundred day simple moving average of $71.85. The company has a market cap of $781.65 million, a P/E ratio of -53.68 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, research analysts predict that Monopar Therapeutics Inc. will post -2.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MNPR. Morgan Stanley reiterated an “overweight” rating and issued a $130.00 target price on shares of Monopar Therapeutics in a report on Monday. HC Wainwright boosted their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. BTIG Research upped their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.